Patents by Inventor Marlys Hammond

Marlys Hammond has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds for the treatment of obesity
    Patent number: 6355635
    Abstract: NPY antagonists, methods of using such NPY antagonists and pharmaceutical compositions containing such NPY antagonists. The NPY antagonists are useful for the treatment of NPY mediated disease/conditions including obesity.
    Type: Grant
    Filed: March 31, 2000
    Date of Patent: March 12, 2002
    Assignee: Pfizer Inc.
    Inventors: Richard L. Elliott, Richard F. Hank, Marlys Hammond
  • Compounds for the treatment of obesity
    Publication number: 20010039277
    Abstract: NPY antagonists, methods of using such NPY antagonists and pharmaceutical compositions containing such NPY antagonists. The NPY antagonists are useful for the treatment of NPY mediated disease/conditions including obesity.
    Type: Application
    Filed: January 4, 2001
    Publication date: November 8, 2001
    Inventors: Richard L. Elliott, Richard F. Hank, Marlys Hammond
  • Neuropeptide antagonists
    Patent number: 6197822
    Abstract: The compound is a neuropeptide Y antagonist and is effective in treating feeding disorders, cardiovascular diseases and other physiological disorders.
    Type: Grant
    Filed: January 25, 2000
    Date of Patent: March 6, 2001
    Assignee: Pfizer Inc.
    Inventor: Marlys Hammond
  • 4-aminopyrrole (3, 2-D) pyrimidines as neuropeptide Y receptor antagonists
    Patent number: 6187778
    Abstract: This invention provides a means of inhibiting or preventing a disease or condition associated with an excess of neuropeptide Y which comprises administering to a mammal in need of such treatment an effective amount of a compound of the formula: wherein R1 is a nitrogen containing heterocyclic compound.
    Type: Grant
    Filed: September 7, 1999
    Date of Patent: February 13, 2001
    Assignee: Pfizer Inc.
    Inventors: Robert Lee Dow, Marlys Hammond
  • Pharmaceutical compositions containing HIV protease inhibitors and methods of their use
    Patent number: 6162812
    Abstract: HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optically other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.
    Type: Grant
    Filed: April 1, 1999
    Date of Patent: December 19, 2000
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Bruce A. Dressman, James E. Fritz, Marlys Hammond, William J. Hornback, Stephen W. Kaldor, Vincent J. Kalish, John E. Munroe, Siegfried Heinz Reich, John H. Tatlock, Timothy A. Shepherd, Michael J. Rodriguez
  • Method of treating conditions susceptible to modulation of NPY receptors with diarylimidazole derivatives
    Patent number: 6121260
    Abstract: Certain diaryl imidazoles act as partial agonists or antagonists for NPY receptors, in particular NPY 5 receptors. They are of use, for example in treating loss of appetite. Such compounds bear aryl groups in the 2 position. Many of the compounds are novel.
    Type: Grant
    Filed: July 2, 1998
    Date of Patent: September 19, 2000
    Assignees: Neurogen Corporation, Pfizer Inc.
    Inventors: Andrew Thurkauf, Jun Yuan, Alan Hutchison, Charles A. Blum, Richard L. Elliot, Marlys Hammond
  • HIV protease inhibitors
    Patent number: 5834467
    Abstract: HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 10, 1998
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Vincent J. Kalish, Bruce A. Dressman, James E. Fritz, Marlys Hammond, William J. Hornback, Stephen W. Kaldor, John E. Munroe, Siegfried Heinz Reich, John H. Tatlock, Timothy A. Shepherd, Michael J. Rodriquez
  • HIV protease inhibtors
    Patent number: 5827891
    Abstract: HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 27, 1998
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Bruce A. Dressman, James E. Fritz, Marlys Hammond, William J. Hornback, Stephen W. Kaldor, Vincent J. Kalish, John E. Munroe, Siegfried Heinz Reich, John H. Tatlock, Timothy A. Shepherd, Michael J. Rodriguez
  • Anti-picornaviral agents
    Patent number: 5821331
    Abstract: The present invention provides a group of novel compounds that inhibit the proteolytic activity of 3C proteases which are found in picornaviruses, particularly rhinoviruses. In picornaviruses the RNA genome is translated into a single large viral polyprotein precursor. The precursor demonstrates auto-proteolytic activity, cleaving itself into mature viral gene products. Therefore, compounds of the current invention are particularly useful in treating picornaviral infections by interrupting the processing of the viral gene products into mature and infectious viral particles. The current invention also provides a novel process the preparation of compounds of the current invention. The process entails the selective reduction of an imide intermediate representing a marked improvement over processes known in the art for making peptidyl-aldehydes.
    Type: Grant
    Filed: February 8, 1996
    Date of Patent: October 13, 1998
    Assignee: Eli Lilly and Company
    Inventors: Marlys Hammond, Stephen W. Kaldor
  • Intermediates for inhibitors of HIV protease and method of preparation thereof
    Patent number: 5719287
    Abstract: The present invention provides novel HIV protease inhibitors, pharmaceutical formulations containing those compounds and methods of their use.
    Type: Grant
    Filed: May 24, 1995
    Date of Patent: February 17, 1998
    Assignee: Eli Lilly and Company
    Inventors: Stephen W. Kaldor, Marlys Hammond
  • Intermediates for preparing HIV protease inhibitors
    Patent number: 5514802
    Abstract: The present invention provides novel HIV protease inhibitors, pharmaceutical formulations containing those compounds and methods of treating and/or preventing HIV infection and/or AIDS.
    Type: Grant
    Filed: April 4, 1995
    Date of Patent: May 7, 1996
    Assignee: Eli Lilly and Company
    Inventors: James E. Fritz, Marlys Hammond, Stephen W. Kaldor
  • Anti-picornaviral agents
    Patent number: 5514778
    Abstract: The present invention provides a group of novel compounds that inhibit the proteolytic activity of 3C proteases which are found in picornaviruses, particularly rhinoviruses. In picornaviruses the RNA genome is translated into a single large viral polyprotein precursor. The precursor demonstrates auto-proteolytic activity, cleaving itself into mature viral gene products. Therefore, compounds of the current invention are particularly useful in treating picornaviral infections by interrupting the processing of the viral gene products into mature and infectious viral particles. The current invention also provides a novel process the preparation of compounds of the current invention. The process entails the selective reduction of an imide intermediate representing a marked improvement over processes known in the art for making peptidyl-aldehydes.
    Type: Grant
    Filed: July 1, 1993
    Date of Patent: May 7, 1996
    Assignee: Eli Lilly and Company
    Inventors: Marlys Hammond, Stephen W. Kaldor
  • Retroviral protease inhibitors
    Patent number: 5508407
    Abstract: The present invention provides novel HIV protease inhibitors, pharmaceutical formulations containing those compounds and methods of their use.
    Type: Grant
    Filed: April 29, 1992
    Date of Patent: April 16, 1996
    Assignee: Eli Lilly and Company
    Inventors: Stephen W. Kaldor, Marlys Hammond
  • HIV protease inhibitors
    Patent number: 5484926
    Abstract: HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.
    Type: Grant
    Filed: February 2, 1994
    Date of Patent: January 16, 1996
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Bruce A. Dressman, James E. Fritz, Marlys Hammond, William J. Hornback, Stephen W. Kaldor, Vincent J. Kalish, John E. Munroe, Siegfried H. Reich, John H. Tatlock, Timothy A. Shepherd, Michael J. Rodriguez
  • Inhibitors of HIV protease useful for the treatment of AIDS
    Patent number: 5475136
    Abstract: The present invention provides novel HIV protease inhibitors, pharmaceutical formulations containing those compounds and methods of treating and/or preventing HIV infection and/or AIDS.
    Type: Grant
    Filed: December 22, 1992
    Date of Patent: December 12, 1995
    Assignee: Eli Lilly and Company
    Inventors: James E. Fritz, Stephen W. Kaldor, Marlys Hammond, Krzysztof Appelt
  • Inhibitors of HIV protease
    Patent number: 5434265
    Abstract: The present invention provides novel HIV protease inhibitors, pharmaceutical formulations containing those compounds and methods of treating HIV infection.
    Type: Grant
    Filed: December 22, 1992
    Date of Patent: July 18, 1995
    Assignee: Eli Lilly and Company
    Inventors: James E. Fritz, Marlys Hammond, Stephen W. Kaldor